{"id":37621,"date":"2025-07-21T14:27:19","date_gmt":"2025-07-21T06:27:19","guid":{"rendered":"https:\/\/flcube.com\/?p=37621"},"modified":"2025-07-21T14:27:20","modified_gmt":"2025-07-21T06:27:20","slug":"vivavision-biotech-closes-d2-funding-round-advancing-ophthalmic-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37621","title":{"rendered":"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies"},"content":{"rendered":"\n<p>VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million RMB. The round was led by Wenzhou Ouhai Xiangtou Yicun Capital (Limited Partnership), with participation from new investors such as Guangdong Technology Financial Group and Renze Zhenhe. Existing shareholders Lapam Capital and Yicun Capital also increased their support.<\/p>\n\n\n\n<p><strong>Strategic Advancement and Local Support<\/strong><br>Since implementing its strategy in Wenzhou Ouhai Gene Valley at the end of 2023, VivaVision Biotech has received strong policy and industrial resource support from the local area. The company&#8217;s core pipeline has entered mid-to-late clinical stages, marked by several key successes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>VVN461LD<\/strong>: Received positive preliminary written feedback from the FDA, requiring only one Phase III pivotal clinical study to treat postoperative ophthalmic inflammation before filing for NDA.<\/li>\n\n\n\n<li><strong>VVN461HD<\/strong>: Included in China&#8217;s National Medical Products Administration &#8220;List of Breakthrough Therapy Drugs,&#8221; positioning it for potential accelerated review and approval.<\/li>\n\n\n\n<li><strong>VVN001<\/strong>: A new generation of domestic dry eye syndrome eye drops, steadily advancing in Phase III clinical trials.<\/li>\n\n\n\n<li><strong>VVN1901<\/strong>: For the treatment of neurotrophic keratitis, recently enrolled its first patient in Phase II clinical trials, officially entering the key clinical stage.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,1917],"class_list":["post-37621","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-vivavision-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million RMB. The round was led by Wenzhou Ouhai Xiangtou Yicun Capital (Limited Partnership), with participation from new investors such as Guangdong Technology Financial Group and Renze Zhenhe. Existing shareholders Lapam Capital and Yicun Capital also increased their support.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37621\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies\" \/>\n<meta property=\"og:description\" content=\"VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million RMB. The round was led by Wenzhou Ouhai Xiangtou Yicun Capital (Limited Partnership), with participation from new investors such as Guangdong Technology Financial Group and Renze Zhenhe. Existing shareholders Lapam Capital and Yicun Capital also increased their support.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37621\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-21T06:27:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-21T06:27:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies\",\"datePublished\":\"2025-07-21T06:27:19+00:00\",\"dateModified\":\"2025-07-21T06:27:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2101.webp\",\"keywords\":[\"Finance\",\"VivaVision Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37621#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37621\",\"name\":\"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2101.webp\",\"datePublished\":\"2025-07-21T06:27:19+00:00\",\"dateModified\":\"2025-07-21T06:27:20+00:00\",\"description\":\"VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million RMB. The round was led by Wenzhou Ouhai Xiangtou Yicun Capital (Limited Partnership), with participation from new investors such as Guangdong Technology Financial Group and Renze Zhenhe. Existing shareholders Lapam Capital and Yicun Capital also increased their support.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37621\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2101.webp\",\"width\":1080,\"height\":608,\"caption\":\"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37621#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million RMB. The round was led by Wenzhou Ouhai Xiangtou Yicun Capital (Limited Partnership), with participation from new investors such as Guangdong Technology Financial Group and Renze Zhenhe. Existing shareholders Lapam Capital and Yicun Capital also increased their support.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37621","og_locale":"en_US","og_type":"article","og_title":"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies","og_description":"VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million RMB. The round was led by Wenzhou Ouhai Xiangtou Yicun Capital (Limited Partnership), with participation from new investors such as Guangdong Technology Financial Group and Renze Zhenhe. Existing shareholders Lapam Capital and Yicun Capital also increased their support.","og_url":"https:\/\/flcube.com\/?p=37621","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-21T06:27:19+00:00","article_modified_time":"2025-07-21T06:27:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37621#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37621"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies","datePublished":"2025-07-21T06:27:19+00:00","dateModified":"2025-07-21T06:27:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37621"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37621#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2101.webp","keywords":["Finance","VivaVision Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37621#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37621","url":"https:\/\/flcube.com\/?p=37621","name":"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37621#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37621#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2101.webp","datePublished":"2025-07-21T06:27:19+00:00","dateModified":"2025-07-21T06:27:20+00:00","description":"VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million RMB. The round was led by Wenzhou Ouhai Xiangtou Yicun Capital (Limited Partnership), with participation from new investors such as Guangdong Technology Financial Group and Renze Zhenhe. Existing shareholders Lapam Capital and Yicun Capital also increased their support.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37621#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37621"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37621#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2101.webp","width":1080,"height":608,"caption":"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37621#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37621"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37621\/revisions"}],"predecessor-version":[{"id":37623,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37621\/revisions\/37623"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37622"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}